ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea
· Delayed Price · Currency is KRW 7,100.00
-10.00 (-0.14%)
At close: Apr 29, 2026
ImmuneOncia Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Net Income | -27,363 | -5,687 | 8,864 | -3,492 | -60,490 | Upgrade
|
| Depreciation & Amortization | 890.41 | 1,051 | 1,031 | 1,081 | 1,026 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0.77 | 1.38 | 3.18 | Upgrade
|
| Stock-Based Compensation | 409.46 | 981.9 | 1,311 | 3,991 | 1,948 | Upgrade
|
| Other Operating Activities | -269.92 | -5,982 | -19,648 | -10,767 | 48,945 | Upgrade
|
| Change in Accounts Receivable | 421.83 | -410.83 | 622.65 | -710.85 | - | Upgrade
|
| Change in Unearned Revenue | - | - | - | -4,952 | 6,884 | Upgrade
|
| Change in Other Net Operating Assets | 3,136 | -4,623 | -518.09 | -452.73 | -292.68 | Upgrade
|
| Operating Cash Flow | -22,775 | -14,670 | -8,337 | -15,301 | -1,976 | Upgrade
|
| Capital Expenditures | -329.97 | -86.87 | -428.43 | -36.21 | -101.34 | Upgrade
|
| Sale (Purchase) of Intangibles | -137.74 | -52.09 | - | -52.4 | -4.85 | Upgrade
|
| Investment in Securities | -12,100 | 1,900 | -5,000 | 6,000 | 2,708 | Upgrade
|
| Other Investing Activities | -545.95 | -32.6 | 96.71 | -8.47 | -840 | Upgrade
|
| Investing Cash Flow | -13,114 | 1,728 | -5,332 | 5,903 | 1,762 | Upgrade
|
| Long-Term Debt Repaid | -51.87 | -48.87 | -103.65 | -232.1 | -210.93 | Upgrade
|
| Net Debt Issued (Repaid) | -51.87 | -48.87 | -103.65 | -232.1 | -210.93 | Upgrade
|
| Issuance of Common Stock | 36,021 | 259 | 8,000 | - | 6,000 | Upgrade
|
| Other Financing Activities | -69.1 | -3.18 | -0 | - | - | Upgrade
|
| Financing Cash Flow | 35,900 | 206.96 | 7,896 | -232.1 | 24,289 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 4.09 | - | 40.44 | 218.5 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | -0 | - | - | Upgrade
|
| Net Cash Flow | 11.34 | -12,731 | -5,773 | -9,590 | 24,293 | Upgrade
|
| Free Cash Flow | -23,105 | -14,757 | -8,766 | -15,337 | -2,078 | Upgrade
|
| Free Cash Flow Margin | -20776.54% | -2254.59% | -7968.93% | -198.32% | -5779.96% | Upgrade
|
| Free Cash Flow Per Share | -329.32 | -262.08 | -167.13 | -294.29 | -44.72 | Upgrade
|
| Cash Interest Paid | 5.12 | 6.93 | - | - | - | Upgrade
|
| Cash Income Tax Paid | 355.61 | -11.04 | 50.18 | 15.8 | 15.98 | Upgrade
|
| Levered Free Cash Flow | -13,443 | -10,722 | -4,331 | -11,188 | 2,384 | Upgrade
|
| Unlevered Free Cash Flow | -13,440 | -10,718 | -4,329 | -11,188 | 2,384 | Upgrade
|
| Change in Working Capital | 3,558 | -5,034 | 104.56 | -6,116 | 6,591 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.